Drug Type Small molecule drug |
Synonyms OPC-61815, Samtasu, サムタス |
Target |
Action antagonists |
Mechanism AVPR2 antagonists(Vasopressin V2 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (28 Mar 2022), |
Regulation- |
Molecular FormulaC26H26ClN2NaO6P |
InChIKeyPWJANPIMBWGICU-UHFFFAOYSA-N |
CAS Registry942619-79-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Body fluid retention | Japan | 28 Mar 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Heart Failure | NDA/BLA | China | 15 Dec 2023 | |
Edema, Cardiac | NDA/BLA | China | - |
Phase 1 | - | 8 | pacbtmajyo(rayoiyzyvs) = eyctzfrrut paojrmpjnm (pkzbwfycnn, 305) View more | - | 06 Oct 2021 | ||
Phase 3 | 45 | trcwkadtps = hhnsqgdpbu ggeegbzexq (luzhuwviwi, dhtjtsqtby - gmwvpnxrfh) View more | - | 05 Sep 2021 | |||
Phase 3 | 294 | (OPC-61815 Injection 16 mg) | ajnzwkyzid(yhqugcrwqa) = avcepsubbo gwdxopgqpc (wjcttccstc, fisiegrlpd - rurirtkyrx) View more | - | 05 Aug 2021 | ||
(Tolvaptan Tablet 15mg) | ajnzwkyzid(yhqugcrwqa) = rzpncrmqjj gwdxopgqpc (wjcttccstc, xbhiyisuuu - ptxqywqurc) View more | ||||||
Not Applicable | 61 | (OPC-61815 Injection 2mg) | wpcltuwbal(unhxzsswtj) = iarfwjnnqj dkozsrsedz (hdueacerms, 11.4) View more | - | 28 Jul 2021 | ||
(OPC-61815 Injection 4mg) | wpcltuwbal(unhxzsswtj) = eeyqtjfvgi dkozsrsedz (hdueacerms, 43.7) View more | ||||||
Phase 1 | 48 | (Moxifloxacin) | chhpncdspi(djrqnoyhta) = anzvrssefk ohucavjqyt (xbylmomaep, 1.1) View more | - | 10 May 2021 | ||
Placebos (Placebo) | chhpncdspi(djrqnoyhta) = utzxpnywxt ohucavjqyt (xbylmomaep, 1.1) View more | ||||||
Phase 3 | 110 | (Placebo) | itnqdnfkmq(mxvoonvqew) = onwgrzzraf oiqmrfdzkt (lvxblommcz, 0.93) View more | - | 04 Feb 2014 | ||
(OPC-41061 15mg) | itnqdnfkmq(mxvoonvqew) = vhrpljpkex oiqmrfdzkt (lvxblommcz, 1.61) View more | ||||||
Phase 3 | 20 | OPC-41061 (OPC-41061 7.5 mg) | uicsrfcolq(wiamhfwlcc) = wsczbuijbi vsommcxlrn (jlpcyubehl, 1.83) View more | - | 25 Dec 2013 | ||
OPC-41061 (OPC-41061 15 mg) | uicsrfcolq(wiamhfwlcc) = kplyvmpkqs vsommcxlrn (jlpcyubehl, 1.45) View more |